Alexander Azoy Sells 2,827 Shares of Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,827 shares of Arcus Biosciences stock in a transaction on Friday, August 21st. The shares were sold at an average price of $30.00, for a total value of $84,810.00. Following the sale, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at $1,187,430. This represents a 6.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alexander Azoy also recently made the following trade(s):

• On Monday, June 1st, Alexander Azoy sold 2,562 shares of Arcus Biosciences stock. The stock was sold at an average price of $25.77, for a total value of $66,022.74.

Arcus Biosciences Stock Performance

NYSE:RCUS opened at $31.42 on Wednesday. The stock has a market cap of $4.00 billion, a P/E ratio of -8.06 and a beta of 0.80. The company has a quick ratio of 3.82, a current ratio of 3.82 and a debt-to-equity ratio of 0.22. The business’s 50-day moving average price is $28.78 and its two-hundred day moving average price is $24.91. Arcus Biosciences, Inc. has a twelve month low of $10.07 and a twelve month high of $31.74.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.17. The company had revenue of $41.00 million during the quarter, compared to analyst estimates of $21.98 million. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%.The business’s revenue was down 74.4% compared to the same quarter last year. As a group, equities analysts predict that Arcus Biosciences, Inc. will post -3.53 EPS for the current fiscal year.

Institutional Trading of Arcus Biosciences

A number of institutional investors have recently modified their holdings of RCUS. Nicholas Investment Partners LP bought a new stake in Arcus Biosciences during the 4th quarter valued at approximately $4,869,000. First Turn Management LLC bought a new position in shares of Arcus Biosciences in the 4th quarter worth approximately $13,467,000. Baker BROS. Advisors LP purchased a new position in shares of Arcus Biosciences in the 4th quarter valued at approximately $6,434,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Arcus Biosciences in the 1st quarter valued at approximately $1,862,000. Finally, Handelsbanken Fonder AB bought a new stake in shares of Arcus Biosciences during the second quarter valued at approximately $1,202,000. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RCUS has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Lifesci Capital assumed coverage on shares of Arcus Biosciences in a report on Thursday, June 4th. They set an “outperform” rating and a $46.00 price objective for the company. Morgan Stanley set a $23.00 target price on shares of Arcus Biosciences in a research report on Monday, August 10th. Truist Financial initiated coverage on Arcus Biosciences in a research note on Monday, May 18th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Wedbush raised their price target on Arcus Biosciences from $41.00 to $43.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $37.80.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.